Carrie Costantini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carrie Costantini has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Alexa B. Schrock
Foundation Medicine, Boston, MA
1 shared publication Ali Haythem
Henry Ford Hospital and Health Network, Detroit, MI
1 shared publication- Ana P. Lourenco
From the Department of Diagnostic Imaging, Alpert Medical School of Brown University, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903
1 shared publication Christa Corn
Provista Diagnostics, New York, NY
1 shared publication- David E. Reese
Provista Diagnostics, New York, NY
1 shared publication Elias Letsios
Provista Diagnostics, New York, NY
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by OAE Publishing Inc.
Immunotherapy in head and neck tumors: new options in advanced disease and beyond
Keywords: Head and neck cancer, immunotherapy, checkpoint inhibitor, pembrolizumab, nivolumab
- 1 January 2018
- Published by OAE Publishing Inc.
Open AccessImmunotherapy in head and neck tumors: new options in advanced disease and beyond
Keywords: Head and neck cancer, immunotherapy, checkpoint inhibitor, pembrolizumab, nivolumab
- Open Access
- 1 November 2017
- Published by Elsevier in Clinical Breast Cancer
- Vol. 17 (7) , 516-525.e6
A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years
- 1 November 2017
- Published by Elsevier in Clinical Breast Cancer
- Vol. 17 (7) , 516-525.e6
Open AccessA Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years
- Open Access
- 16 March 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 197
Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report
Collision tumors are uncommon but well described clinical entities composed of distinct tumor histologies occurring within the same anatomic site. Optimal management of patients with collision tumors remains highly variable and depends on clinical characteristics such as the involved tumor types, predominant histology, as well as the extent of disease. Comprehensive genomic profiling is a means of identifying genomic alterations to suggest benefit from targeted therapy. A 78-year-old woman presented to medical oncology with liver metastases occurring within the background of a 1-year history of uveal melanoma. Biopsy of the liver metastases revealed presence of adenocarcinoma along with nests of malignant melanoma consistent with a collision tumor. The disease was refractory to several lines of conventional cytotoxic chemotherapy, and the patient later developed pulmonary metastases while on chemotherapy. The patient’s tumor tissue was assayed by comprehensive genomic profiling which revealed presence of a TSC1 partial loss. The patient was subsequently initiated on temsirolimus 15 mg intravenously weekly for 4 months. Restaging imaging demonstrated a partial response to therapy by RECIST 1.1 criteria and clinical benefit for 6 months until the patient passed away secondary to unrelated causes. We report the first case of a collision tumor composed of adenocarcinoma and melanoma with a TSC1 mutation that objectively and durably responded to mTOR inhibition.
- 16 March 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 197
Open AccessObjective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report
Collision tumors are uncommon but well described clinical entities composed of distinct tumor histologies occurring within the same anatomic site. Optimal management of patients with collision tumors remains highly variable and depends on clinical characteristics such as the involved tumor types, predominant histology, as well as the extent of disease. Comprehensive genomic profiling is a means of identifying genomic alterations to suggest benefit from targeted therapy. A 78-year-old woman presented to medical oncology with liver metastases occurring within the background of a 1-year history of uveal melanoma. Biopsy of the liver metastases revealed presence of adenocarcinoma along with nests of malignant melanoma consistent with a collision tumor. The disease was refractory to several lines of conventional cytotoxic chemotherapy, and the patient later developed pulmonary metastases while on chemotherapy. The patient’s tumor tissue was assayed by comprehensive genomic profiling which revealed presence of a TSC1 partial loss. The patient was subsequently initiated on temsirolimus 15 mg intravenously weekly for 4 months. Restaging imaging demonstrated a partial response to therapy by RECIST 1.1 criteria and clinical benefit for 6 months until the patient passed away secondary to unrelated causes. We report the first case of a collision tumor composed of adenocarcinoma and melanoma with a TSC1 mutation that objectively and durably responded to mTOR inhibition.
- Open Access
- 1 February 2017
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 6 (1) , 17-29
Advances on immunotherapy in genitourinary and renal cell carcinoma
Genitourinary (GU) cancers are a group of epithelial malignancies associated with the organs involved in the excretion of urine. Renal cell, urothelial, and prostatic carcinoma are the overwhelming subtypes diagnosed by oncologists. Each of these was traditionally treated surgically when local and non-invasive. When these carcinomas spread, invade, or metastasize, surgical control lacks in efficacy. Chemotherapeutic regimens have been implemented for decades and have increased overall survival but many patients progress. Molecular targeting through tyrosine kinase inhibition of the vascular endothelial growth factor (VEGF) has emerged as a frontline therapy in kidney cancer with more durable responses. More recently, immunotherapy has begun to find efficacy in many other solid tumors including melanoma and non-small cell lung cancer. The inherent genetic instability of this group of cancers makes them ideal solid tumors for immune modulation. Vaccines manufactured to initiate T-Cell regulation through neoplastic-antigen presentation are available for prostate cancer and are currently on trial in renal cell carcinoma (RCC). Programmed death-1 (PD-1) and its ligand (PD-L1) are intricate members of cellular immunity against neoplastic cells. In an activated, unbound state, these molecules permit T-cell activation and cytotoxic killing of cancer cells. However, when they are linked, cellular immunity is attenuated and local cancer cells are permitted the opportunity to proliferate and invade. A novel class of monoclonal antibodies have been developed which stop PD-1 linkage and thus uncouple the ‘stop’ signal of these neoplastic regulatory cells. The increased overall and progression free survival have made them attractive options alone as well as in combination with anti-VEGF inhibitors for patients. Although more tolerable than chemotherapy, immunotherapeutics have adverse potential toxicities. Overall, the use of immunomodulatory medications have opened a new paradigm in the anti-neoplastic regimen of GU cancers and further developments will determine the appropriate patient to treat for optimum tumor burden eradication.
- 1 February 2017
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 6 (1) , 17-29
Open AccessAdvances on immunotherapy in genitourinary and renal cell carcinoma
Genitourinary (GU) cancers are a group of epithelial malignancies associated with the organs involved in the excretion of urine. Renal cell, urothelial, and prostatic carcinoma are the overwhelming subtypes diagnosed by oncologists. Each of these was traditionally treated surgically when local and non-invasive. When these carcinomas spread, invade, or metastasize, surgical control lacks in efficacy. Chemotherapeutic regimens have been implemented for decades and have increased overall survival but many patients progress. Molecular targeting through tyrosine kinase inhibition of the vascular endothelial growth factor (VEGF) has emerged as a frontline therapy in kidney cancer with more durable responses. More recently, immunotherapy has begun to find efficacy in many other solid tumors including melanoma and non-small cell lung cancer. The inherent genetic instability of this group of cancers makes them ideal solid tumors for immune modulation. Vaccines manufactured to initiate T-Cell regulation through neoplastic-antigen presentation are available for prostate cancer and are currently on trial in renal cell carcinoma (RCC). Programmed death-1 (PD-1) and its ligand (PD-L1) are intricate members of cellular immunity against neoplastic cells. In an activated, unbound state, these molecules permit T-cell activation and cytotoxic killing of cancer cells. However, when they are linked, cellular immunity is attenuated and local cancer cells are permitted the opportunity to proliferate and invade. A novel class of monoclonal antibodies have been developed which stop PD-1 linkage and thus uncouple the ‘stop’ signal of these neoplastic regulatory cells. The increased overall and progression free survival have made them attractive options alone as well as in combination with anti-VEGF inhibitors for patients. Although more tolerable than chemotherapy, immunotherapeutics have adverse potential toxicities. Overall, the use of immunomodulatory medications have opened a new paradigm in the anti-neoplastic regimen of GU cancers and further developments will determine the appropriate patient to treat for optimum tumor burden eradication.
- 1 February 2017
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 6 (1) , 48-55
Immunotherapy in head and neck cancer
Head and neck squamous cell carcinoma (HNSCC) comprise a diverse group of malignancies including tumors caused by tobacco and alcohol as well as an increasing number of human papillomavirus (HPV)-associated cancers. There has been recent improved understanding on how HNSCC develops by evading the immune system. The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to the checkpoint inhibitor pembrolizumab for the treatment of recurrent or metastatic HNSCC. We provide a comprehensive review of immune escape mechanism in HNSCC and latest developments in immunotherapy in HNSCC with a focus on checkpoint inhibitors, therapeutic cancer vaccines, and adoptive cellular therapies.
- 1 February 2017
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 6 (1) , 48-55
Immunotherapy in head and neck cancer
Head and neck squamous cell carcinoma (HNSCC) comprise a diverse group of malignancies including tumors caused by tobacco and alcohol as well as an increasing number of human papillomavirus (HPV)-associated cancers. There has been recent improved understanding on how HNSCC develops by evading the immune system. The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to the checkpoint inhibitor pembrolizumab for the treatment of recurrent or metastatic HNSCC. We provide a comprehensive review of immune escape mechanism in HNSCC and latest developments in immunotherapy in HNSCC with a focus on checkpoint inhibitors, therapeutic cancer vaccines, and adoptive cellular therapies.